Fang, Weijia
First Affiliated Hospital Zhejiang University · Zhejiang University
4 papers on CoChatORCID 0000-0001-9849-347X
Most cited papers
- Verified
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2023) · The Lancet
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 746
- Verified
Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma
Zheng, Y., Wang, T., Tu, X., Huang, Y., Zhang, H., Tan, D., Jiang, W., Cai, S., Zhao, P., Song, R., et al. (2019) · Journal for ImmunoTherapy of Cancer
Gut microbiota and healthCancer Immunotherapy and Biomarkers
Cited by 550
- Verified
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
Llovet, J. M., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B.-Y., Ren, Z., et al. (2023) · The Lancet Oncology
Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies
Cited by 469
- Verified
Spatial single-cell proteomics landscape decodes the tumor microenvironmental ecosystem of intrahepatic cholangiocarcinoma
Hong, L., Mei, J., Sun, X., Wu, Y., Dong, Z., Jin, Y., Gao, L., Cheng, J., Tian, W., Liu, C., et al. (2026) · Hepatology
Cholangiocarcinoma and Gallbladder Cancer StudiesSingle-cell and spatial transcriptomics
Cited by 42
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free